(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 14.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Genmab A's revenue in 2025 is $3,317,340,000.On average, 6 Wall Street analysts forecast GMAB's revenue for 2025 to be $230,397,364,853, with the lowest GMAB revenue forecast at $226,528,670,874, and the highest GMAB revenue forecast at $235,895,191,958. On average, 6 Wall Street analysts forecast GMAB's revenue for 2026 to be $276,253,029,293, with the lowest GMAB revenue forecast at $251,163,904,410, and the highest GMAB revenue forecast at $295,287,917,226.
In 2027, GMAB is forecast to generate $317,834,737,332 in revenue, with the lowest revenue forecast at $286,192,127,094 and the highest revenue forecast at $339,494,689,030.